Microsoft Stock Forecast (NASDAQ: MSFT): Alibaba And Tencent Can Slow Down Microsoft Azure

motek 1The article was written by Motek Moyen Research Seeking Alpha’s #1 Writer on Long Ideas and #2 in Technology  – Senior Analyst at I Know First

Microsoft Stock Forecast


  • I Know First has pessimistic market trend forecasts for Microsoft’s stock. Investors should do profit-taking while this stock still trades above $90.
  • Microsoft’s recent management team shake-up is not inspiring investors to rally behind the stock.
  • I can explain this algorithmic bearishness to Microsoft’s inability to dislodge Amazon Web Services’ leadership in cloud computing infrastructure services.
  • Based on most-recent quarter signals, hedge fund managers have a very negative sentiment over Microsoft. No real revenue/profit numbers for Azure is discouraging.
  • Azure is unlikely to gain a foothold in China’s $103 billion cloud computing industry. Alibaba Cloud will dominate China and threaten current global leaders.

Verizon stock forecastRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

Quick Win by the Algorithm: Bitauto Holdings Limited (NYSE: BITA) Dives Deep Under Market Surface Down To -30.73% In 1 Month

Quick Algorithm

“As we continue to make healthy progress across our business lines, we are optimistic about Bitauto’s profitability outlook for 2018. We expect to expand margins over the coming quarters as we drive cost saving synergies between Bitauto and Yixin, increased efficiencies in our media business, and economies of scale from Yixin.”

– Ms. Cynthia He, Chief Financial Officer of Bitauto

BITA logo

[Image Source:]

Over the March Bitauto stock price experienced ups and downs. During the first third of the month the stock price oscillated around $29 per share and jumped up

Read More

Quick Win by the Algorithm: Sangamo Therapeutics (NASDAQ: SGMO) Returns Up To 278.00% In 1 Year And Promises Bright Future

” This year we continue the important work of laying the foundation for Sangamo as a sustainable, fully integrated company that develops, manufacturers and commercializes novel genomic therapies on our own and, where appropriate, in collaboration with industry partners. “

-Sandy Macrae, CEO of Sangamo.

[Image source:]

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a clinical stage biopharmaceutical company that focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene

Read More

Quick Win by the Algorithm: New BCO Management Drives Impressive 125.41% Return

Quick Win by the Algorithm

Read The Full Forecast

Quick WIn